Cargando…

Impact of Atrial Fibrillation on Stroke‐Related Healthcare Costs

BACKGROUND: Limited data exist on the economic implications of stroke among patients with atrial fibrillation (AF). This study assesses the impact of AF on healthcare costs associated with ischemic stroke (IS), hemorrhagic stroke (HS), or transient ischemic attack (TIA). METHODS AND RESULTS: A retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sussman, Matthew, Menzin, Joseph, Lin, Iris, Kwong, Winghan J., Munsell, Michael, Friedman, Mark, Selim, Magdy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886763/ https://www.ncbi.nlm.nih.gov/pubmed/24275631 http://dx.doi.org/10.1161/JAHA.113.000479

Ejemplares similares

Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy
por: Menzin, Joseph, et al.
Publicado: (2014)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective
por: Casciano, Julian P., et al.
Publicado: (2013)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

MSR37 Identifying Clinical Subtypes of Long COVID: An Unsupervised Machine Learning Approach
por: Munsell, M., et al.
Publicado: (2023)

P9 Characteristics of Patients Diagnosed with Long COVID: Early Findings from Real-World Data
por: Munsell, M., et al.
Publicado: (2023)

Factors Influencing Oral Anticoagulant Prescribing Practices for Atrial Fibrillation
por: Leung, Lester Y., et al.
Publicado: (2017)

Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis
por: Lang, Kathleen, et al.
Publicado: (2014)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Understanding the Effect of Osteoarthritis on Surgical Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients With Tenosynovial Giant Cell Tumors
por: Lin, Feng, et al.
Publicado: (2023)

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis
por: AbuDagga, Azza, et al.
Publicado: (2014)

Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation
por: Field, Michael E., et al.
Publicado: (2020)

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
por: Wang, Kaijun, et al.
Publicado: (2017)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy
por: Stephenson, Judith J, et al.
Publicado: (2018)

Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
por: Friedman, Daniel J., et al.
Publicado: (2020)

ML4 Application of Machine Learning Models to Evaluate COVID-19 Related ICU Utilization in a US Population
por: Icten, Z., et al.
Publicado: (2020)

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
por: Munsell, Michael, et al.
Publicado: (2016)

Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs
por: Munsell, Michael, et al.
Publicado: (2017)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Atrial Fibrillation Related and Unrelated Stroke Recurrence Among Ischemic Stroke Patients With Atrial Fibrillation
por: Kim, Bum Joon, et al.
Publicado: (2021)

Review of the cost of venous thromboembolism
por: Fernandez, Maria M, et al.
Publicado: (2015)

Comorbidity in US patients with multiple sclerosis
por: Edwards, Natalie C, et al.
Publicado: (2018)

Major drivers of healthcare system costs and cost variability for routine atrial fibrillation ablation
por: Zenger, Brian, et al.
Publicado: (2022)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation
por: Deshmukh, Abhishek, et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019)

Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis
por: Lang, Kathleen, et al.
Publicado: (2014)

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
por: Verhoef, Talitha I., et al.
Publicado: (2014)

Cost considerations in the management of atrial fibrillation – impact of dronedarone
por: Khaykin, Yaariv, et al.
Publicado: (2012)

Racial/ethnic and sex differences in safety outcomes and atrial fibrillation/atrial flutter–related acute healthcare utilization after catheter ablation of atrial fibrillation
por: Jackson, Larry R., et al.
Publicado: (2023)

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
por: Christiansen, Christine Benn, et al.
Publicado: (2010)

Impact of the Pattern of Atrial Fibrillation on Stroke Risk and Mortality
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

The impact of competing stroke etiologies in patients with atrial fibrillation
por: Zietz, Annaelle, et al.
Publicado: (2023)

Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011)

Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
por: Azahar, Siti Norain, et al.
Publicado: (2022)

Atrial Fibrosis, Ischaemic Stroke and Atrial Fibrillation
por: Mahnkopf, Christian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vs0um55r0e73lmecldsdgkhruj